Bausch + Lomb Corporation (BLCO) News
Follow Bausch + Lomb Corporation (BLCO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 27 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
TSX Futures Slip as Oil and Gold Prices Fall; Retail Sales Data Eyed
Canadian stock futures edged lower as oil and gold prices fell, while investors awaited retail sales data.
EQUITY | Nov 20, 2026, 10:49 AM UTC
M
Paxman Q3 Revenue Rises on Strong US Sales
EQUITY | Nov 20, 2026, 06:09 AM UTC
M
Bausch + Lomb Reports Third-Quarter Revenue of $1.38 Billion
Third-quarter revenue rose 7.3% year over year to $1.38 billion. Net income was $32 million, versus a $28 million loss, and diluted EPS was $0.09, compared with a loss of $0.08 per share.
EQUITY | Oct 28, 2026, 08:32 PM UTC
M
Bausch + Lomb Q3 earnings snapshot
Bausch + Lomb is the subject of a Q3 earnings snapshot; the supplied body is truncated before reporting results.
EQUITY | Oct 28, 2026, 06:40 PM UTC
M
Bausch + Lomb Shares Rise 8.7% After Revenue and Guidance Update
Bausch + Lomb reported third-quarter 2026 revenue of $1.375 billion and raised its full-year 2026 revenue guidance.
EARNINGS | Oct 28, 2026, 05:17 PM UTC
M
Bausch + Lomb Adjusted Third-Quarter Earnings Jump 89% YoY
Bausch + Lomb’s adjusted earnings rose 89% year over year and beat estimates.
EARNINGS | Oct 28, 2026, 02:55 PM UTC
M
Bausch + Lomb Reports Quarterly Results for Period Ended September 30
A machine-generated LSEG earnings summary was published; the supplied text does not include the results.
EQUITY | Oct 28, 2026, 01:32 PM UTC
M
Bausch + Lomb Reports Q3 Revenue Growth, Raises 2026 Guidance
Bausch + Lomb reported third-quarter 2026 revenue of $1.375 billion, up 7% year over year. Net income attributable to the company was $32 million, adjusted EBITDA was $325 million and adjusted diluted EPS was $0.34. The
EQUITY | Oct 28, 2026, 11:13 AM UTC
L
Bausch & Lomb Names Thomas Appio Interim CEO After Saunders Departs
Bausch & Lomb said Brent Saunders departed as CEO and director, and appointed Thomas J. Appio interim CEO effective October 12, 2026.
EQUITY | Oct 13, 2026, 10:15 AM UTC
M
Bausch + Lomb Shares Fall Nearly 10% After Interim CEO Appointment
Bausch + Lomb appointed Thomas J. Appio interim CEO, effective immediately, replacing Brent Saunders, as the shares fell nearly 10% Monday. The company and parent Bausch Health said they expect to raise full-year 2026 ad
EQUITY | Oct 12, 2026, 06:13 PM UTC
H
Bausch + Lomb shares are trading lower. The company announced the appointment of Chairman Thomas Appio as interim CEO following Brent Saunders' departure, while also indicating it expects to raise full-year 2026 adjusted EBITDA guidance.
Bausch + Lomb shares are trading lower. The company announced the appointment of Chairman Thomas Appio as interim CEO following Brent Saunders' departure, while also indicating it expects to raise full-year 2026 adjusted
LIVE | Oct 12, 2026, 02:06 PM UTC
M
Bausch + Lomb CEO Saunders Departs; Chairman Appio Named Interim Chief
Bausch + Lomb said CEO Brent Saunders will depart by mutual agreement with the board. Chairman Thomas Appio will serve as interim chief, effective immediately.
EQUITY | Oct 12, 2026, 01:46 PM UTC
M
Bausch + Lomb CEO Saunders Steps Down; Chairman Appio Named Interim Chief
Bausch + Lomb said Brent Saunders will depart after a mutual agreement with the board. Chairman Thomas Appio will serve as interim CEO effective immediately.
EQUITY | Oct 12, 2026, 12:42 PM UTC
H
Bausch + Lomb Appoints Chairman Thomas J. Appio As Interim CEO, Effective Immediately; Company And Its Parent Bausch Health Expect To Raise FY26 Adjusted EBITDA Guidance, Excluding Acquired IPR&D
Preliminary Update on 2026 Guidance2 Based on preliminary third-quarter results, Bausch + Lomb and Bausch Health currently expect to raise full-year 2026 adjusted EBITDA excluding Acquired IPR&D1 guidance.3 The companies
LIVE | Oct 12, 2026, 10:48 AM UTC
L
US FDA sent warning letter to Bausch & Lomb on September 4
US FDA
REGULATION | Sep 15, 2026, 02:34 PM UTC
L
Leerink Partners sets $24.00 price target for Bausch & Lomb
Leerink Partners announced a $24.00 per-share price target for Bausch & Lomb, according to Benzinga ratings actions cited by TradingView News.
EQUITY | Sep 09, 2026, 03:16 PM UTC
L
Bausch & Lomb target maintained at $21.00 by HC Wainwright
HC Wainwright & Co. maintained its Bausch & Lomb price target at $21.00 per share.
EQUITY | Aug 28, 2026, 10:24 AM UTC
L
Bausch + Lomb advances dry-eye Phase 3 candidate, BL1332 Phase 1b
Bausch + Lomb moves its dual-action dry-eye candidate into Phase 3 after mixed Phase 2 results and reports positive Phase 1b ocular-surface pain data for BL1332.
EQUITY | Aug 24, 2026, 09:07 PM UTC
M
Bausch + Lomb Adds Bausch Health CEO To Board
Bausch Health CEO joins Bausch + Lomb board
EQUITY | Aug 06, 2026, 11:05 AM UTC
L
BLCO Bausch + Lomb Earnings Notes: - Q2 Operating Income $83M - Q2 REV $1.394B vs. EST $1.369B - Q2 Net Income $-14M - Q2 ADJ Net Income $55
BLCO Bausch + Lomb Earnings Notes: - Q2 Operating Income $83M - Q2 REV $1.394B vs. EST $1.369B - Q2 Net Income $-14M - Q2 ADJ Net Income $55M vs. EST $54.9M - Q2 ADJ EPS $0.15 vs. EST $0.15 - Q2 ADJ EBITDA $241M vs. EST
EARNINGS | Jul 29, 2026, 11:03 AM UTC
L
Bausch & Lomb Raises FY2026 Sales Guidance from $5.420B-$5.520B to $5.440B-$5.540B vs $5.468B Est
Bausch & Lomb (NYSE: BLCO ) raises FY2026 sales outlook from $5.420 billion-$5.520 billion to $5.440 billion-$5.540 billion vs $5.468 billion estimate.
EARNINGS | Jul 29, 2026, 10:59 AM UTC
H
BLCO Raises Full-Year 2026 Guidance
BLCO Raises Full-Year 2026 Guidance
EQUITY | Jul 29, 2026, 10:58 AM UTC
L
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutr
RXST GKOS SGHT BLCO COO STAA Medical Supplies and Devices initiation - resuming coverage across the Vision sector (Neutral rated GKOS, Neutral rated RXST, Buy rated SGHT) and initiating coverage of Buy rated BLCO, Neutra
EQUITY | Jul 28, 2026, 11:52 AM UTC
L
BLCO Initiated Buy at UBS
BLCO Initiated Buy at UBS
EQUITY | Jul 28, 2026, 11:49 AM UTC
L
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: O
Top Initiations: ATEC BDX BLCO EW SGHT SIBN STE ZBH: BUY @ UBS COO GKOS GMED IART RXST TFX TMDX: NEUTRAL @ UBS INSP STAA: SELL @ UBS BNTC: OUTPERFORM @ Wedbush CRWD: BUY @ Loop FTH: OUTPERFORM @ Opp HRB: EQUAL WEIGHT @ S
EQUITY | Jul 28, 2026, 11:11 AM UTC
L
BLCO bausch + lomb launches eyegility™ inserter preloaded iol delivery system in the United States
BLCO bausch + lomb launches eyegility™ inserter preloaded iol delivery system in the United States
EQUITY | Jul 16, 2026, 11:05 AM UTC
H
Bausch + Lomb Ends Glaucoma Drug Development, Shifts Focus
Bausch + Lomb Corporation (NYSE: BLCO ) on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma after the candidate failed to meet the primary endpoint in a Phase 2 clinical trial.
MNA | Jul 10, 2026, 02:23 PM UTC
H
Bausch + Lomb price target raised to $21 from $19 at Citi
Citi raised the firm's price target on Bausch + Lomb to $21 from $19 and keeps a Buy rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks
EARNINGS | Jul 08, 2026, 10:11 AM UTC